AUTONOMIX MEDICAL INC (AMIX) Stock Price, Quote, News and Overview
NASDAQ:AMIX - Nasdaq - US05330T2050 - Common Stock - Currency: USD
AMIX Quote, Performance and Key Statistics
NASDAQ:AMIX (6/23/2025, 10:52:56 AM)
1.27
+0.03 (+2.42%)
The current stock price of AMIX is 1.27 USD. In the past month the price decreased by -31.11%. In the past year, price decreased by -94.1%.
AMIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.85 | 231.57B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.83 | 183.00B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.61 | 150.25B | ||
| SYK | STRYKER CORP | 29.94 | 143.35B | ||
| MDT | MEDTRONIC PLC | 15.56 | 109.76B | ||
| BDX | BECTON DICKINSON AND CO | 11.98 | 48.38B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.01 | 44.24B | ||
| IDXX | IDEXX LABORATORIES INC | 46.04 | 42.53B | ||
| RMD | RESMED INC | 28.04 | 37.33B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.35 | 32.33B | ||
| DXCM | DEXCOM INC | 48.27 | 31.23B | ||
| STE | STERIS PLC | 25.3 | 23.22B |
Related stock screener links
About AMIX
Company Profile
Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. The company is headquartered in The Woodlands, Texas and currently employs 5 full-time employees. The company went IPO on 2024-01-29. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. The company is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.
Company Info
AUTONOMIX MEDICAL INC
21 Waterway Ave, Suite 300
The Woodlands TEXAS US
Employees: 7
Phone: 18322777816
AUTONOMIX MEDICAL INC / AMIX FAQ
What is the stock price of AUTONOMIX MEDICAL INC today?
The current stock price of AMIX is 1.27 USD. The price increased by 2.42% in the last trading session.
What is the ticker symbol for AUTONOMIX MEDICAL INC stock?
The exchange symbol of AUTONOMIX MEDICAL INC is AMIX and it is listed on the Nasdaq exchange.
On which exchange is AMIX stock listed?
AMIX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AUTONOMIX MEDICAL INC stock?
8 analysts have analysed AMIX and the average price target is 11.73 USD. This implies a price increase of 823.62% is expected in the next year compared to the current price of 1.27. Check the AUTONOMIX MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AUTONOMIX MEDICAL INC worth?
AUTONOMIX MEDICAL INC (AMIX) has a market capitalization of 3.12M USD. This makes AMIX a Nano Cap stock.
How many employees does AUTONOMIX MEDICAL INC have?
AUTONOMIX MEDICAL INC (AMIX) currently has 7 employees.
What are the support and resistance levels for AUTONOMIX MEDICAL INC (AMIX) stock?
AUTONOMIX MEDICAL INC (AMIX) has a resistance level at 1.89. Check the full technical report for a detailed analysis of AMIX support and resistance levels.
Should I buy AUTONOMIX MEDICAL INC (AMIX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMIX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMIX, evaluating the profitability, health, valuation and growth aspects
- AUTONOMIX MEDICAL INC (AMIX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AUTONOMIX MEDICAL INC (AMIX) Sales and EPS estimates to see what analysts future expectations are.
- AUTONOMIX MEDICAL INC (AMIX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AUTONOMIX MEDICAL INC (AMIX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AUTONOMIX MEDICAL INC (AMIX) Stock Chart to make your own analysis
- AUTONOMIX MEDICAL INC (AMIX) Latest news and press-releases to stay up to date.
Does AUTONOMIX MEDICAL INC (AMIX) stock pay dividends?
AMIX does not pay a dividend.
What is the Price/Earnings (PE) ratio of AUTONOMIX MEDICAL INC (AMIX)?
AUTONOMIX MEDICAL INC (AMIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.95).
What is the Short Interest ratio of AUTONOMIX MEDICAL INC (AMIX) stock?
The outstanding short interest for AUTONOMIX MEDICAL INC (AMIX) is 7.14% of its float. Check the ownership tab for more information on the AMIX short interest.
AMIX Technical Analysis
AMIX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AMIX. No worries on liquidiy or solvency for AMIX as it has an excellent financial health rating, but there are worries on the profitability.
AMIX Financial Highlights
Over the last trailing twelve months AMIX reported a non-GAAP Earnings per Share(EPS) of -7.95. The EPS increased by 60.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -116.35% | ||
| ROE | -140.87% | ||
| Debt/Equity | 0 |
AMIX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to AMIX. The Buy consensus is the average rating of analysts ratings from 8 analysts.